Related Experiment Video
Updated: Mar 9, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence
G Ostuzzi1, D Papola1, C Gastaldon1
1Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry,University of Verona,Verona,Italy.
Abstract:
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (EMA) in a public assessment report, released in April 2016. In this commentary, the main strengths and limitations of the EMA assessment report were appraised and discussed, in order to highlight possible implications for clinical practice, future research and regulatory practices for drug approval.
More Related Videos
Related Concept Videos
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Psychosis: Goals of Pharmacotherapy
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

